Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Microsoft — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $109.67 (market cap $12.58B), while Microsoft trades at $523.86 (market cap $3.93T). The key difference: Microsoft is far larger — about 312.4× Halozyme Therapeutics Inc. Common Stock's market cap, and Microsoft pays a 0.74% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Microsoft for 142 Days on average.
| HALO | MSFT | |
|---|---|---|
Market Cap | $12.58B | $3.93T |
Volume | 2,179,278 | 16,040,951 |
Sector | Health | Technology |
52-Week High | $115.22 | $542.07 |
52-Week Low | $61.63 | $352.83 |
Typical Hold Time | 0 Days | 142 Days |
Enterprise Value | $14.49B | $3.91T |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Microsoft (MSFT) trades at $522.61, down 1.26% on the day, amid a bullish technical setup with strong moving average signals and key support at $522. The company reported robust fundamentals with Q2 2026 EPS of $4.74 beating estimates, revenue growth to $281.72B in 2025, and net income margins of 40.31%. Recent news highlights AI leadership and Azure momentum, though RSI levels suggest overbought conditions.
Outlook remains positive with an 81.71% analyst buy rating and a $571.76 consensus price target, implying ~9% upside. Risks include elevated capital expenditure concerns and competitive pressures in AI. Strong cash flow generation and a declining debt-to-asset ratio support long-term growth, but investors should monitor execution on AI investments and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
